These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24913462)

  • 1. Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Elkhouli M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2014 Oct; 44(4):402-10. PubMed ID: 24913462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in maternal corin and mid-regional proatrial natriuretic peptide in women at risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Elkhouli M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Feb; 45(2):190-8. PubMed ID: 25296530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes in maternal hemodynamics in a population at risk for pre-eclampsia.
    Khalil A; Garcia-Mandujano R; Maiz N; Elkhouli M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2014 Aug; 44(2):197-204. PubMed ID: 24652784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
    Foidart JM; Munaut C; Chantraine F; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Jun; 35(6):680-7. PubMed ID: 20205159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early pregnancy screening for hypertensive disorders in women without a-priori high risk.
    Abdelaziz A; Maher MA; Sayyed TM; Bazeed MF; Mohamed NS
    Ultrasound Obstet Gynecol; 2012 Oct; 40(4):398-405. PubMed ID: 22689569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal changes in uterine artery Doppler and blood pressure and risk of pre-eclampsia.
    Khalil A; Garcia-Mandujano R; Maiz N; Elkhouli M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2014 May; 43(5):541-7. PubMed ID: 24265180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
    Lai J; Syngelaki A; Poon LC; Nucci M; Nicolaides KH
    Fetal Diagn Ther; 2013; 33(3):149-55. PubMed ID: 23154616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.
    Chaiworapongsa T; Romero R; Savasan ZA; Kusanovic JP; Ogge G; Soto E; Dong Z; Tarca A; Gaurav B; Hassan SS
    J Matern Fetal Neonatal Med; 2011 Oct; 24(10):1187-207. PubMed ID: 21827221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
    Savvidou MD; Noori M; Anderson JM; Hingorani AD; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Dec; 32(7):871-6. PubMed ID: 18814185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
    Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
    BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors.
    Hirashima C; Ohkuchi A; Takahashi K; Suzuki H; Yoshida M; Ohmaru T; Eguchi K; Ariga H; Matsubara S; Suzuki M
    Hypertens Res; 2011 Feb; 34(2):212-7. PubMed ID: 21048778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating soluble endoglin and placental abruption.
    Signore C; Mills JL; Qian C; Yu KF; Rana S; Karumanchi SA; Levine RJ
    Prenat Diagn; 2008 Sep; 28(9):852-8. PubMed ID: 18702104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women.
    Laskowska M; Laskowska K; Oleszczuk J
    J Matern Fetal Neonatal Med; 2012 Jun; 25(6):806-11. PubMed ID: 21793708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia.
    Lim JH; Kim SY; Park SY; Lee MH; Yang JH; Kim MY; Chung JH; Lee SW; Ryu HM
    Prenat Diagn; 2009 May; 29(5):471-6. PubMed ID: 19253312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.